Aptevo Therapeutics Inc. (APVO) - Dilution Analysis

8-K filing: Aptevo Therapeutics entered into a collaboration agreement with Niowave and completed a private placement of common stock and warrants for aggregate proceeds of approximately $500,000. ($0.5M proceeds)

10-K filing | 1.2M shares outstanding

S-1 filing: This is an S-1 filing for an offering of common stock by YA II PN, LTD., with the company potentially receiving up to $60 million from sales of shares to YA under a purchase agreement.

8-K filing: Stock split 1-for-18 | Outstanding: 16,850,494 → 936,138

10-Q filing | 16.9M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 6,903,755 shares of common stock by YA II PN, LTD.

10-Q filing | 3.3M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 8,250,825 shares of common stock by YA II PN, LTD pursuant to a Standby Equity Purchase Agreement, with the company potentially receiving up to $25.0 million in gross proceeds.

8-K filing: Aptevo Therapeutics Inc. closed an offering on June 20, 2025, involving the sale of 2,105,000 shares of common stock and pre-funded warrants to purchase up to 360,000 shares, along with common warrants to purchase up to 12,325,000 shares, resulting in net proceeds of approximately $7.45 million for the company.

S-1 filing: The company is offering up to 1,709,401 shares of common stock, up to 1,709,401 pre-funded warrants to purchase common stock, and up to 8,547,005 common warrants to purchase common stock.

8-K filing: Stock split 1-for-20 | Outstanding: 8,109,290 → 405,464

8-K filing: Aptevo Therapeutics Inc. announced a prospective 1-for-20 reverse stock split effective May 23, 2025, and has been offering shares of common stock under its At The Market Offering Agreement, selling 7,989,040 shares for $3,349,104 in gross proceeds as of May 22, 2025. ($3.35M proceeds)

10-Q filing | 8.1M shares outstanding

RW filing: This is a request to withdraw the registration statement for a proposed public offering.

S-1 filing: This prospectus relates to the resale from time to time by certain selling stockholders named herein (the "Holders") of up to 3,529,420 shares of Common Stock issuable upon exercise of certain common stock purchase warrants.

RW filing: Aptevo Therapeutics Inc. is requesting the Commission's consent to withdraw the Registration Statement on Form S-3 (File No. 333-286952) because the company has determined not to pursue the contemplated resale of shares of the Company's common stock, issuable upon exercise of certain common stock purchase warrants.

S-3 filing: This prospectus relates to the resale from time to time by certain selling stockholders named herein (the "Holders") of up to 3,529,420 shares of Common Stock issuable upon exercise of certain common stock purchase warrants.

8-K filing: Aptevo Therapeutics Inc. sold 305,845 shares of its Common Stock at an aggregate gross offering price of $0.5946 pursuant to the Sales Agreement and the Prior Prospectus Supplement for aggregate gross sale proceeds of $181,848. ($0.18M proceeds)

8-K filing: Aptevo Therapeutics Inc. sold 2,324,000 shares of its Common Stock in a registered direct offering at a price of $0.862 per share, closing on April 22, 2025, and receiving net proceeds of approximately $1.8 million.

8-K filing: Aptevo Therapeutics Inc. completed a registered direct offering and concurrent private placement on April 4, 2025, selling 1,764,710 shares of common stock and unregistered warrants to purchase up to 3,529,420 shares of common stock, with net proceeds of approximately $1.9 million. ($2.1M proceeds)

S-1/A filing: This is a best efforts public offering of common stock, pre-funded warrants, Series A warrants, and Series B warrants. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of our product candidates.

S-1/A filing: The filing is an S-1/A form filed on 2025-03-27 for a public offering of up to 12,987,013 shares of common stock, along with pre-funded warrants and Series A and Series B common warrants, with Roth Capital Partners, LLC acting as the exclusive placement agent.

S-1/A filing: This is a reasonable best efforts public offering of shares of our common stock together with Series A and Series B common warrants.

S-1/A filing: The company is offering up to 8,000,000 shares of common stock, up to 8,000,000 pre-funded warrants to purchase common stock, up to 8,000,000 Series A warrants to purchase common stock and up to 120,000,000 Series B warrants to purchase common stock.

S-1 filing: The company is filing an S-1 to offer up to 1,557,632 shares of common stock, up to 1,557,632 pre-funded warrants to purchase common stock, and up to 3,115,264 common warrants to purchase common stock.

S-3 filing: The filing is for a shelf offering of common stock, preferred stock, debt securities, warrants, and subscription rights with a total value of $100,000,000.

10-K filing | 1.5M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time by certain selling stockholders of up to 1,647,088 shares of Common Stock issuable upon exercise of new common stock purchase warrants.

8-K filing: Aptevo Therapeutics Inc. entered into a warrant inducement agreement with certain holders to exercise existing warrants to purchase up to 823,544 shares of common stock at $7.50 per share, with the company issuing new warrants to purchase 200% of the shares issued upon exercise of the existing warrants. ($6.2M proceeds)

8-K filing: Stock split 1-for-37 | Outstanding: 18,512,084 → 500,326

10-Q filing | 18.5M shares outstanding

8-K filing: Aptevo Therapeutics Inc. completed a registered direct offering on September 18, 2024, involving the sale of common stock and pre-funded warrants, resulting in net proceeds of approximately $2.5 million for the company.

S-1 filing: This S-1 filing includes an offering of up to 13,513,513 shares of common stock, up to 13,513,513 pre-funded warrants to purchase common stock, and up to 27,027,026 common warrants to purchase common stock.

10-Q filing | 9.4M shares outstanding

8-K filing: Aptevo Therapeutics Inc. closed a registered direct offering on July 1, 2024, selling 5,339,806 shares of common stock (or pre-funded warrants) and warrants to purchase 10,679,612 shares of common stock, resulting in net proceeds of approximately $2.3 million.

S-1/A filing: The company is offering up to 6,024,096 shares of common stock together with common warrants, and pre-funded warrants with common warrants, with Roth Capital Partners, LLC acting as the exclusive placement agent. The offering will terminate no later than July 12, 2024.

S-1 filing: The company is offering up to 6,024,096 shares of common stock, up to 6,024,096 pre-funded warrants to purchase up to 6,024,096 shares of common stock and up to 12,048,192 common warrants to purchase up to 12,048,192 shares of common stock in a best efforts public offering.

10-Q filing | 4.1M shares outstanding

8-K filing: Aptevo Therapeutics Inc. closed a public offering of common stock and warrants on April 15, 2024, raising net proceeds of approximately $4.0 million.

S-1/A filing: The company is offering shares of common stock, pre-funded warrants, and common warrants in a public offering.

S-1/A filing: This S-1/A filing includes an offering of up to 922,509 shares of common stock, up to 922,509 pre-funded warrants to purchase up to 922,509 shares of common stock, and up to 1,845,018 common warrants to purchase up to 1,845,018 shares of common stock.

S-1 filing: The filing is for a public offering of up to 922,059 shares of common stock together with up to 1,845,018 common warrants to purchase up to 1,845,018 shares of common stock and pre-funded warrants to purchase shares of common stock.

10-K filing | 23.5M shares outstanding

8-K filing: Stock split 1-for-44 | Outstanding: 15,657,772 → 355,854

S-3 filing: This S-3 filing relates to the resale of up to 32,026,068 shares of Aptevo Therapeutics Inc.'s Common Stock issuable upon exercise of warrants by certain selling stockholders.

10-Q filing | 17.6M shares outstanding

8-K filing: Aptevo Therapeutics Inc. entered into a warrant inducement agreement with certain holders to exercise existing warrants to purchase up to 16,013,034 shares of common stock at $0.233 per share, with the company anticipating receiving up to approximately $3.4 million in gross proceeds. ($3.4M proceeds)

10-Q filing | 11.5M shares outstanding

8-K filing: Aptevo Therapeutics Inc. completed a public offering of 2,221,550 shares of common stock and pre-funded warrants to purchase 5,842,967 shares of common stock at a combined price of $0.62 and $0.619 respectively, resulting in net proceeds of approximately $4.6 million after deducting offering expenses.

S-1/A filing: This S-1/A filing registers the offering of common stock, common stock underlying pre-funded warrants, Series A and B common warrants, and common warrants to purchase common stock.

S-1/A filing: The company is offering up to 7,692,308 shares of common stock, pre-funded warrants, and common warrants at a combined price of $1.56 per share/warrant, with the offering terminating no later than August 31, 2023.

S-1 filing: S-1 filing for a best efforts public offering of up to 8,275,862 shares of common stock and common stock purchase warrants at an assumed price of $1.45 per share.

10-Q filing | 7.0M shares outstanding

10-K filing | 7.2M shares outstanding

10-Q filing | 5.1M shares outstanding

10-Q filing | 5.0M shares outstanding

10-Q filing | 5.0M shares outstanding

10-K filing | 5.0M shares outstanding

8-K filing: Aptevo Therapeutics Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the Company to sell up to $35,000,000 of shares of its common stock over a thirty-six month term.

10-Q filing | 4.9M shares outstanding

S-3 filing: This S-3 filing registers 1,250,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC, which may be issued pursuant to a purchase agreement between Aptevo Therapeutics, Inc. and Lincoln Park.

10-Q filing | 4.9M shares outstanding

10-Q filing | 4.4M shares outstanding

10-K filing | 4.4M shares outstanding

S-3 filing: Apivo files an S-3 to offer a combination of common stock, preferred stock, and debt securities up to $200,000,000. The company intends to use the net proceeds from this offering primarily for research, development and manufacturing of product candidates, and for other general corporate purposes.

10-Q filing | 4.1M shares outstanding

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

8-K filing: Aptevo Therapeutics Inc. effected a 1-for-14 reverse stock split of the Company's outstanding common stock that was effective on March 26, 2020, resulting in adjustments to warrants with an exercise price of $18.20 and 1,417,857 shares of common stock exercisable.

8-K filing: Stock split 1-for-14 | Outstanding: 45,279,244 → 3,232,938

10-K filing | 45.3M shares outstanding